Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma

BACKGROUND: Glycogen synthase kinase (GSK)-3β has emerged as an appealing therapeutic target for glioblastoma (GBM). Here, we investigated the therapeutic effect of the current approved drugs against GBM via inhibition of GSK3β activity both, in experimental setting and in a clinical study for recur...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Furuta, Takuya, Sabit, Hemragul, Dong, Yu, Miyashita, Katsuyoshi, Kinoshita, Masashi, Uchiyama, Naoyuki, Hayashi, Yasuhiko, Hayashi, Yutaka, Minamoto, Toshinari, Nakada, Mitsutoshi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410264/
https://ncbi.nlm.nih.gov/pubmed/28423558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15206
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller